2. Academic Validation
  3. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

  • Nat Med. 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032.
Yi Du 1,  Hirohito Yamaguchi 1,  Yongkun Wei 1,  Jennifer L Hsu 1,  Hung-Ling Wang 2,  Yi-Hsin Hsu 1,  Wan-Chi Lin 1,  Wen-Hsuan Yu 1 3,  Paul G Leonard 4 5,  Gilbert R Lee 4th 4 5,  Mei-Kuang Chen 1 3,  Katsuya Nakai 1,  Ming-Chuan Hsu 1,  Chun-Te Chen 1,  Ye Sun 1,  Yun Wu 6,  Wei-Chao Chang 2 7,  Wen-Chien Huang 8,  Chien-Liang Liu 8,  Yuan-Ching Chang 8,  Chung-Hsuan Chen 7,  Morag Park 9,  Philip Jones 5,  Gabriel N Hortobagyi 10,  Mien-Chie Hung 1 2 3 11
Affiliations

Affiliations

  • 1 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 2 Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.
  • 3 The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA.
  • 4 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 5 Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 7 Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • 8 Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
  • 9 Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
  • 10 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 11 Department of Biotechnology, Asia University, Taichung, Taiwan.
PMID: 26779812 DOI: 10.1038/nm.4032
Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including Cancer, in clinical trials. One PARP Inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian Cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes Cancer cells to PARP inhibition. Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP Inhibitor, thereby rendering Cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast Cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung Cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.

Figures
Products